OTCPK:PETV

Stock Analysis Report

Executive Summary

PetVivo Holdings, Inc., a biomedical device company, focuses on licensing and commercializing medical devices and therapeutics to treat pets and other animals suffering from arthritis and other afflictions.

Rewards

Earnings have grown 27.6% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has PetVivo Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PETV has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

7.1%

PETV

-0.06%

US Medical Equipment

0.6%

US Market


1 Year Return

68.8%

PETV

25.1%

US Medical Equipment

20.8%

US Market

Return vs Industry: PETV exceeded the US Medical Equipment industry which returned 25.1% over the past year.

Return vs Market: PETV exceeded the US Market which returned 20.8% over the past year.


Shareholder returns

PETVIndustryMarket
7 Day7.1%-0.06%0.6%
30 Day1.3%3.7%2.5%
90 Day10.3%4.2%4.9%
1 Year68.8%68.8%26.2%25.1%23.5%20.8%
3 Year1.3%1.3%91.7%86.1%46.5%37.0%
5 Year-86.7%-86.7%117.6%93.8%64.6%46.5%

Price Volatility Vs. Market

How volatile is PetVivo Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PetVivo Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether PetVivo Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as PetVivo Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of PETV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through PetVivo Holdings regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is PetVivo Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PetVivo Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of PETV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access PetVivo Holdings's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has PetVivo Holdings performed over the past 5 years?

27.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PETV is currently unprofitable.

Growing Profit Margin: PETV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PETV is unprofitable, but has reduced losses over the past 5 years at a rate of 27.6% per year.

Accelerating Growth: Unable to compare PETV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PETV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).


Return on Equity

High ROE: PETV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is PetVivo Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: PETV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PETV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PETV has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PETV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: PETV has a high level of physical assets or inventory.

Debt Coverage by Assets: PETV has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PETV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PETV has less than a year of cash runway if free cash flow continues to reduce at historical rates of -43.6% each year


Next Steps

Dividend

What is PetVivo Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PETV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PETV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PETV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PETV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PETV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of PetVivo Holdings's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

John Lai (57yo)

0.4yrs

Tenure

US$60,000

Compensation

Mr. John Lai has been the President of PetVivo Holdings, Inc. since July 17, 2017 and has been its Chief Executive Officer since July 16, 2019. Mr. Lai has been Director of PetVivo Holdings, Inc. since Mar ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD60.00K) is below average for companies of similar size in the US market ($USD526.35K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.0yrs

Average Tenure

55.5yo

Average Age

Experienced Management: PETV's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Age and Tenure

3.6yrs

Average Tenure

61yo

Average Age

Experienced Board: PETV's board of directors are considered experienced (3.6 years average tenure).


Insider Trading

Insider Buying: PETV insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$1,00004 Dec 19
James Martin
EntityIndividual
Shares2,500
Max PriceUS$0.40
BuyUS$4,00015 Nov 19
James Martin
EntityIndividual
Shares9,000
Max PriceUS$0.44
BuyUS$1,02507 Nov 19
James Martin
EntityIndividual
Shares2,250
Max PriceUS$0.46
BuyUS$98709 Oct 19
James Martin
EntityIndividual
Shares2,250
Max PriceUS$0.44
BuyUS$2,94509 Oct 19
James Martin
EntityIndividual
Shares8,325
Max PriceUS$0.38

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Management Team

  • Gary DeMel (62yo)

    Executive Vice President of Business Development

    • Tenure: 3.3yrs
  • John Lai (57yo)

    CEO, President & Director

    • Tenure: 0.4yrs
    • Compensation: US$60.00k
  • John Dolan (54yo)

    Secretary & Director

    • Tenure: 5.8yrs
    • Compensation: US$102.79k
  • Randy Wenthold

    Chief Science Officer

    • Tenure: 2yrs
  • John Carruth (30yo)

    Chief Financial Officer

    • Tenure: 1yrs
    • Compensation: US$231.02k

Board Members

  • Robert Rudelius (63yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$134.61k
  • Greg Cash (62yo)

    Chairman of the Board

    • Tenure: 0.4yrs
  • Joe Jasper

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$138.03k
  • John Lai (57yo)

    CEO, President & Director

    • Tenure: 0.4yrs
    • Compensation: US$60.00k
  • David Deming (62yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$51.39k
  • David Masters (61yo)

    Director

    • Tenure: 4.7yrs
    • Compensation: US$25.70k
  • John Dolan (54yo)

    Secretary & Director

    • Tenure: 5.8yrs
    • Compensation: US$102.79k
  • Randall Meyer (55yo)

    Director

    • Tenure: 4.7yrs
    • Compensation: US$25.70k
  • John Wagoner

    Member of Advisory Board

    • Tenure: 3.6yrs
  • Brian Barnett

    Member of Advisory Board

    • Tenure: 3.6yrs

Company Information

PetVivo Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PetVivo Holdings, Inc.
  • Ticker: PETV
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$10.115m
  • Shares outstanding: 22.48m
  • Website: https://www.petvivo.com

Number of Employees


Location

  • PetVivo Holdings, Inc.
  • 5251 Edina Industrial Boulevard
  • Edina
  • Minneapolis
  • Minnesota
  • 55439
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PETVOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2014

Biography

PetVivo Holdings, Inc., a biomedical device company, focuses on licensing and commercializing medical devices and therapeutics to treat pets and other animals suffering from arthritis and other afflictions ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/14 01:15
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.